Randomized Placebo-Controlled Trial of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Chemotherapy-Related Febrile Neutropenia

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 619-627

  Vellenga, E ^a   Uyl de Groot, C A ^b   De Wit, R ^b   Keizer, H J ^b   Lowenberg B ^b   Ten Haaft, M A ^b   De Witte, Th J M ^b   Verhagen, C A H ^b   Stoter, G J ^b   Rutten, F F H ^b   Mulder, N H ^b   Smid, W M ^b   De Vries, E G E ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CYTOKINES; DOUBLE-BLIND METHOD; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LENGTH OF STAY; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUALITY OF LIFE;

EID: 0030033919     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.619     Document Type: Article

References (22)

1. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
2. Pizzo PA: Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 54:2649-2661, 1984
3. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: N Engl J Med 327:28-35, 1992
4. Crawford F, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer: N Engl J Med 325:164-170, 1991
5. Gerhartz HH, Engelhard M, Meusers P, et al: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas: Blood 82:2329-2339, 1993
6. Gorin NC, Coiffier B, Hayat M, et al: Recombinant human granulocyte-macrophage colony stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: A double-blind placebo-controlled trial. Blood 80:1149-1157, 1992
7. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
8. Biesma B, de Vries EGE, Willemse PHB, et al: Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leucopenia and fever. Eur J Cancer 26:932-936, 1992
9. Riikonen P, Saarinen UM, Mäkipernaa A, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo controlled study in children. Pediatr Infect Dis J 13:197-200, 1994
10. Maher DW, Lieschke GJ, Green M, et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 121:492-501, 1994
11. Mayordomo FI, Rivera F, Diaz-Puent MT, et al: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony stimulating factors. J Natl Cancer Inst 11:803-808, 1995
12. Bonsel GJ, Rutten FFH, Uyl-de Groot CA: Economic evaluation alongside cancer trial: methodological and practical aspects. Eur J Cancer 29A:S10-S14, 1993
13. Uyl-de Groot CA, Rutten FFH, Bonsel GJ: Measurement and valuation of quality of life in economic appraisal of cancer treatment. Eur J Cancer 30A:111-117, 1994
14. Hunt SM, McEwen J, McKenna SP: Measuring Health Status. London, United Kingdom, Croom Helm, 1986, pp 241-245
15. de Haes JCJM, van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034-1038, 1990
16. van Hout BA, McDonnell J: Estimating a Parametric Relation Between Health Description and Health Valuation Using the Euro-Qol Instrument. IHE Working Paper Lund, 1991, pp 45-59
17. Bonsel GJ, Essink-Bot ML, Klompmaker J, et al: Assessment of the quality of life before and during liver transplantation. Transplantation 53:796-800, 1992
18. Glantz SA: Primer of Biostatistics. Singapore, McGraw Hill, 1989, pp 287-330
19. Pizzo PA, Robichaud KJ, Gill FA, et al: Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 67:194-200, 1976
20. Pizzo PA, Robichaud KJ, Gill FA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111, 1982
21. Hazenberg BPC, van Leeuwen MA, van Rijswijk MH, et al: Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 and flare-up of arthritis. Blood 74:2769-2770, 1989
22. Tiegs G, Barsig J, Matiba B, et al: Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J Clin Invest 9:2616-2623, 1994